PhD Position in ImmunobiologyPhD student in chemokine immunobiology - HORIZON-MSCA-2022-DN Doctoral Network “B-ACTIVE” These projects, funded by the Marie Skłodowska-Curie Actions (MSCA)-doctoral network program "B-ACTIVE", is a EU-funded collaboration between the universities of Leuven, Copenhagen, Graz, Ljubljana, Uppsala and several industrial partners located in Copenhagen, Uppsala, Graz, Cambridge and Paris (see https://b-active-dn.eu). In the B-ACTIVE consortium, fundamental and clinical scientists and companies will study the impact of posttranslational modifications of chemokine ligands and receptors while training 10 doctoral candidates into future experts with translational and interdisciplinary mindsets. The doctoral candidates will characterize interactions between chemokine ligands, receptors and glycosaminoglycans, study signaling pathways and recognize their importance in inflammatory reactions. B-ACTIVE thus provides training in the complexity of inflammatory responses from basic science to clinical applications and industrial development. B-ACTIVE aims to unite fundamental and clinical scientists with pharmaceutical companies to explore the impact of posttranslational modifications of chemokine ligands and receptors. The project’s goal is to enhance our comprehension of inflammatory responses, pinpoint the right drug targets, and actively contribute to pharmaceutical development, ultimately improving patient treatment. The MSCA doctoral networks aim to train creative, entrepreneurial, innovative and resilient doctoral candidates, able to face current and future challenges and to convert knowledge into societal benefit. Uppsala University, Department of Medical Cell Biology The research group of Professor Mia Phillipson is offering a 4-year funded PhD Student position in chemokines immunobiology with rotation of 6 months to Ilya Pharma AB, a biopharmaceutical development company in Uppsala. The team is an international, dynamic and very successful research group with a well-established collaborative network and strong funding. The conducted research is aiming to uncover novel roles of immune cells and to find means to regulate their specific functions in settings spanning from organ development and regulation of homeostasis to tissue healing, angiogenesis and inflammation. The laboratory is equipped with or have access to advanced technical tools and technologies. PhD project: Investigation of chemokine proteoform and microbiome profiles of non-healing wounds in patients with diabetes In this project, the PhD student will characterize the chemokine profiles as well as chemokine bioactivity in plasma and wound fluid from otherwise healthy subjects and in patients with diabetes using different assays, and correlate the results with the healing status of the respective wound. In addition, the PhD student will characterize the wound microbiome composition and correlate this to the healing status of the wound, as well as to the profiles of chemokine (proteoforms) and chemokine processing enzymes and processing kinetics in plasma and wound fluid. Today there are no pharmaceuticals based on chemokine ligands as such, but there are some drug candidates in development aiming to alter the bioactivity of immunomodulatory proteins including chemokines, and this project aims at supporting this field of science and drug development. Ilya Pharma AB Profile Requirements We welcome applications from Doctoral Researcher candidates fulfilling the following criteria:
Selection process Be aware that official transcripts of any degree achieved, preferably including average or final marks and explanation of the related assessment scale or criterion (mandatory for the main graduate degree, optional for the others) will be required for the enrolment in the University/PhD program. All documents should be in English. The selection of the Doctoral Researcher candidates will be carried out in compliance with the general rules for MSCA-DN projects and will be based just on individual merit. The selection process will be entirely carried out in English. Candidates fulfilling the eligibility criteria will be pre-selected for online interviews. A Selection Committee was appointed by the B-ACTIVE Consortium for the evaluation of the application of the candidates. Applications which do not meet the minimal prerequisites listed in the Eligibility Criteria section, or which are not submitted according to the procedure specified in the Offer Description section, or which are received after the submission deadline has expired, will be rejected. Whenever necessary, it will be also entitled to ask the candidates to provide any further document, information or clarification deemed useful to properly complete the assessment process. Personal data will be stored for the purpose of carrying out the application procedure only. About the employment For further information about the position, please contact: Mia Phillipson, mia.phillipson@mcb.uu.se Please submit your application by 31 May 2024, UFV-PA 2024/1062. Are you considering moving to Sweden to work at Uppsala University? Find out more about what it´s like to work and live in Sweden. Uppsala University is a broad research university with a strong international position. The ultimate goal is to conduct education and research of the highest quality and relevance to make a difference in society. Our most important asset is all of our 7,600 employees and 53,000 students who, with curiosity and commitment, make Uppsala University one of Sweden’s most exciting workplaces. Read more about our benefits and what it is like to work at Uppsala University Please do not send offers of recruitment or advertising services. Submit your application through Uppsala University's recruitment system. Placement: Department of Medical Cell Biology Type of employment: Full time , Temporary position Pay: According to local collective agreement Number of positions: 1 Working hours: 100% Town: Uppsala County: Uppsala län Country: Sweden Union representative: ST/TCO tco@fackorg.uu.se Number of reference: UFV-PA 2024/1062 Last application date: 2024-05-31
|